Xlife Sciences AG (XSWX:XLS) EPS (Basic): CHF-3.76 (TTM As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
50 GF Score
Price CHF20.90
GF Value CHF7.30
Valuation Significantly Overvalued
! 13 Warning Signs
View Full Analysis

What is Xlife Sciences AG EPS (Basic)?

Xlife Sciences AG XSWX:XLS -11.06% 50 EPS (Basic) is CHF-3.76 as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review.

Xlife Sciences AG's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was CHF-3.23. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.76.

Xlife Sciences AG's EPS (Diluted) for the six months ended in Dec. 2025 was CHF-3.23. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.76.

Xlife Sciences AG's EPS without NRI for the six months ended in Dec. 2025 was CHF-3.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -3.74.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Xlife Sciences AG  (XSWX:XLS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Xlife Sciences AG EPS (Basic) Related Terms

Xlife Sciences AG EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG EPS (Basic) Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial 11.30 2.72 2.73 6.00 -3.76

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 0.08 5.92 -0.53 -3.23
XSWX:XLS
50GF Score
Xlife Sciences AG XSWX:XLS
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Xlife Sciences AG's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-21.547-0)/5.737
=-3.76

Xlife Sciences AG's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-18.497-0)/5.732
=-3.23

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-3.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of CHF-3.76 mean?
Xlife Sciences AG (XSWX:XLS) has a EPS (Basic) of CHF-3.76 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's EPS (Basic) too high?
Xlife Sciences AG's current EPS (Basic) is CHF-3.76. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's EPS (Basic) compare to VRTX and REGN?
Xlife Sciences AG's EPS (Basic) of CHF-3.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current EPS (Basic) is CHF-3.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current EPS (Basic) is CHF-3.76. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current EPS (Basic) is CHF-3.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • EPS (Basic): CHF-3.76
  • GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
  • GF Score™: 50/100 with 13 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score

Get the complete analysis for XSWX:XLS

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.90
Price
CHF7.30
GF Value